Brains Bioceutical
Brains Bioceutical is a Vancouver-based cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade cannabinoid APIs (CBD, THC, CBN, CBG) at its UK facility, supplying pharmaceutical companies, clinical researchers, nutraceutical brands, and veterinary markets across six continents.
- Company typePrivate
- Founded2015
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Brains Bioceutical does
Brains Bioceutical Corp. is a Vancouver-headquartered, privately held cannabinoid life sciences company operating through its wholly-owned UK subsidiary BSPG Laboratories Ltd. The company manufactures pharmaceutical-grade cannabinoid active pharmaceutical ingredients (APIs) — including CBD, D9-THC (in solid crystalline form), D8-THC, CBN, and CBG — at a 25,000 sq ft EU-GMP certified facility in Sandwich, Kent, originally established as a Pfizer Discovery Park site. Brains Bio produces 500+ commercial GMP batches annually with zero quality failures, holds 36-month stability data, sub-0.15% impurity profiles, and an industry-low 0.000006% THC detection threshold, supplying APIs into 30+ clinical trials across epilepsy, opioid addiction, anxiety, insomnia, and inflammation indications.
The company monetizes through four interlinked revenue streams: (1) pharmaceutical API supply under long-term contracted agreements extending through 2030, (2) a pharmaceutical development division pursuing licensing and co-development partnerships (e.g., DSM-Firmenich exclusive global alliance, Effcon for glaucoma under FDA Special Protocol Assessment, Prati for refractory epilepsy in Brazil), (3) a nutraceuticals division operating a three-tier brand architecture (Brains Pure at Harrods, Vitabiotics x Brains in pharmacy chains across 100+ countries, Vitality CBD on Amazon and in Tesco/ASDA/Bootes/Holland & Barrett), and (4) an animal health division targeting companion animal therapeutics. Regulatory positioning is unusually deep: EU-GMP, EudraGMDP, MHRA API registration, US Drug Master File, EU ASMF, ANVISA, TGA, UK Novel Food validation (first for naturally sourced CBD), NSF/ANSI 173 certification, NSF Certified for Sport, and an in-progress EDQM CEP application.
Go-to-market combines enterprise field sales to multinational pharmaceutical companies with a multi-tiered channel partner strategy across UK retail pharmacy, premium department stores, Amazon e-commerce, and regional distributors across six continents. Distribution partners include Cronos Australia, a major Brazilian pharmaceutical manufacturer, and Vitabiotics (UK's #1 vitamin company). The company is cash-flow positive, supported by US$62M of cumulative disclosed funding, and led by an executive team combining Big Pharma veterans from Biogen, GlaxoSmithKline, and GW Pharma with cannabis-industry specialists.
Brains Bioceutical firmographics
Firmographics- Name
- Brains Bioceutical
- Legal name
- Brains Bioceutical Corp.
- Website
- https://brainsbioceutical.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Brains Bioceutical is a Vancouver-based cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade cannabinoid APIs (CBD, THC, CBN, CBG) at its UK facility, supplying pharmaceutical companies, clinical researchers, nutraceutical brands, and veterinary markets across six continents.
- Ownership category
- akta.pro rank
Brains Bioceutical industry classification
Industry- Product category
- Pharmaceutical Cannabinoid APIs
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
- akta.pro secondary industries
- Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Brains Bioceutical is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Brains Bioceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Supply Chain, Personnel, Infrastructure, Marketing or Sales, Others
Revenue model
- Pharmaceutical API Supply: Supply of EU-GMP certified cannabinoid APIs (CBD, THC, CBN, CBG) to pharmaceutical companies for clinical trials and commercial applications. Revenue secured through long-term supply agreements and contracted revenue pipeline through 2030.
- Nutraceutical Products: Three-tier brand architecture: Brains Pure (premium Harrods placement), Vitabiotics x Brains (pharmacy chains), Vitality CBD (Amazon and major retailers). Co-branded and white-label products through Vitabiotics partnership.
- Pharmaceutical Licensing: High-margin licensing revenue through pharmaceutical partnerships and direct commercialization of proprietary formulations. Includes CEP certification enabling streamlined regulatory processes for pharmaceutical manufacturers globally.
- Contract Manufacturing: Custom formulation development and finished product manufacturing for pharmaceutical and nutraceutical partners. End-to-end solutions from API to finished dosage forms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Multi-year contract | B2B pharmaceutical API supply contracts |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels5 records
Brains Bioceutical product offering
Product offeringCore offering
Brains Bioceutical is a cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade active pharmaceutical ingredients (APIs) including CBD, D9-THC, D8-THC, CBN, and CBG at its UK facility. The company leverages these APIs across four pillars: pharmaceutical APIs for drug developers, therapeutic development programs, branded nutraceutical products, and veterinary applications. Revenue is anchored by multi-year B2B supply contracts with pharmaceutical, nutraceutical, and animal health companies globally.
Product overview
Brains Bioceutical operates as a diversified cannabinoid life sciences company organized into four strategic pillars: Brains API (pharmaceutical-grade cannabinoid APIs), Pharmaceuticals (therapeutic development programs), Nutraceuticals (wellness products), and Animal Health (veterinary applications). The Brains API division serves as the foundational engine, producing EU-GMP certified APIs including CBD, D9-THC, D8-THC, CBN, and CBG that power all other segments. The Pharmaceuticals division leverages these APIs for clinical programs targeting opioid use disorder, refractory epilepsy, glaucoma, and insomnia. The Nutraceuticals division converts APIs into consumer products through owned brands (Brains Pure, Vitality CBD, Jorja's Botanicals) and co-branded offerings with Vitabiotics. The Animal Health division applies the same EU-GMP platform to veterinary applications. The company also operates BrainsAI, an AI-powered precision medicine ecosystem for CNS disorder drug discovery, and BSPG Laboratories, its wholly-owned UK manufacturing subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- Brains Pure: Premium CBD brand positioned at Harrods for high-net-worth wellness consumers.
- Brains Inside
- Jorja's Botanicals
- PURUS
- BSPG Laboratories
Products and services
- EU GMP CBD API Pharmaceutical-grade Cannabidiol (CBD) active pharmaceutical ingredient manufactured at EU-GMP certified facilities with 99.7% purity and ultra-low THC content. Sold to pharmaceutical companies, contract manufacturers, and researchers for clinical trials and finished dosage forms.
- D9-THC API (Solid Crystalline Form) Delta-9-Tetrahydrocannabinol API in solid crystalline form—a world's first breakthrough enabling precise dosing and improved stability compared to liquid THC formulations. Supplied to pharmaceutical developers and researchers for cannabinoid-based drug development.
- CBN API Cannabinol API available as EU-GMP certified active pharmaceutical ingredient for emerging therapeutic applications. Supplied to pharmaceutical developers for novel drug development programs.
- CBG API Cannabigerol API in final validation as part of the company's pharmaceutical-grade cannabinoid portfolio, with early-mover advantage in emerging therapeutics. Supplied to pharmaceutical and nutraceutical developers.
- D8-THC API Delta-8-Tetrahydrocannabinol API for medical applications requiring controlled substance capabilities. Supplied to pharmaceutical companies and researchers.
- Opioid Use Disorder Program Cannabinoid therapeutic development program for opioid use disorder under NIH-funded Phase 3 trial, leveraging proprietary oral CBD formulation. Targets the >$450M peak revenue opportunity in the $8.4B opioid use disorder market.
- Refractory Epilepsy Program Cannabinoid therapeutic development program for refractory epilepsy with Phase III study under ANVISA review in Brazil. Positioned to become the first globally market-authorized CBD pharmaceutical through partnership with Prati.
- Brains Pure Premium CBD consumer brand positioned at Harrods targeting high-net-worth wellness consumers seeking pharmaceutical-grade quality and verified purity.
- Vitality CBD Mass market CBD brand distributed through Amazon and major UK retailers (Holland & Barrett, Boots, Tesco, ASDA) targeting price-conscious wellness consumers.
- Vitabiotics x Brains Co-branded CBD nutraceutical products with Vitabiotics (UK's #1 vitamin company), distributed across 100+ countries through pharmacy chains and retailers.
- PURUS Range Combination CBD:THC products in various ratios (PURUS SA, PURUS 20, PURUS 50) for personalized cannabinoid medication and therapeutic applications.
- Animal Health Cannabinoid APIs Veterinary cannabinoid APIs and products targeting companion animal wellness and prescription therapeutics across multiple species, including canine osteoarthritis, epilepsy, anxiety, and feline stress conditions.
- Brains Bio API Division Core API division supplying EU-GMP certified cannabinoid APIs (CBD, D9-THC, D8-THC, CBN, CBG) to pharmaceutical, nutraceutical, and animal health markets worldwide through contracted revenue agreements.
Quantifiable outcome
- 500+ commercial GMP batches with zero quality failures
- +6 more outcomes
Companies that use Brains Bioceutical
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Brains Bioceutical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature7 records
Brains Bioceutical partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, strategic, minor and flagship.
- Icahn School of Medicine at Mount SinaicoreClinical trial partnership for PK study using Brains Bio's oral CBD formulation as foundation for potential opioid addiction studies. Mount Sinai's multidisciplinary research team investigating neurobiology of addiction disorders.
- Tamar TechnologiesstrategicStrategic partnership providing access to biopharmaceutical technologies, cannabinoids and phytochemical products, and delivery mechanisms. Investment and partnership opened doors for specialty pharmaceutical advancements and global market expansion.
- Cronos AustraliacoreSupply agreement for CBD products distribution in Australia. Cronos Australia (joint venture between Cronos Group and NewSouthern Capital) to distribute Brains Bio products under the 'Adaya' product line following TGA approval.
- InnoCan PharmaminorLetter of Intent for Tamar to distribute Brains Bio's naturally sourced CBD API to Ramot and/or Yissum for use in InnoCan's CBD research projects including exosome-based technology and liposome delivery platforms.
- Brazilian Pharmaceutical PartnercorePartnership with leading Brazilian pharmaceutical company (producing 11.5 billion therapeutic doses annually with 4,200+ employees) for supply of EU-GMP CBD API for Brazil's first registered medical cannabis product under ANVISA regulations.
- VitabioticsflagshipExclusive multi-year agreement with UK's #1 vitamin company (27% market share) for co-branded and white-label CBD products. Partnership provides immediate access to Vitabiotics' distribution across 100+ countries and established credibility in the nutraceutical market.
- DSM-FirmenichflagshipExclusive global partnership for joint commercialization and innovation platform for early-stage cannabinoid drug development. DSM-Firmenich provides formulation expertise, global regulatory specialists, and preclinical/clinical study capabilities. Combined expertise aims to realize potential of CBD-based formulations.
- King's College LondonstrategicResearch partnership with scientific partners at King's College London investigating CBD effects on mental health conditions including anxiety, depression, PTSD, and COVID-19 clinical study proposals.
- ALTIS/Brains Bioceutical Living LabstrategicState-of-the-art interdisciplinary athletics training facility exploring, experimenting, and evaluating power of CBD API in elite athletes. Partnership combines sports medicine expertise with pharmaceutical-grade CBD research.
- Melbourne Brain Centre at Royal Melbourne HospitalstrategicClinical trial supply partnership for CBD research studies in Australia at the Melbourne Brain Centre.
- Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)strategicClinical research partnership with Australia's leading cannabinoid research center for CBD clinical trials.
- Prati (Brazil)corePartnership for regulatory filing in Brazil for refractory epilepsy treatment using CBD API. Prati is advancing toward first globally market-authorized CBD pharmaceutical.
- Effcon (USA)strategicPartnership for extended-release glaucoma treatment advancing under FDA Special Protocol Assessment with Effcon.
Scale indicators13 records
Recent moves6 records
Expansion highlights7 records
Brains Bioceutical competitors and assessment
Company assessmentDirect peers
- MediPharm Labs: Canadian GMP-certified cannabinoid API manufacturer competing for similar pharmaceutical and nutraceutical customers. Most direct competitor in the cannabinoid API supply business, though MediPharm's regulatory certifications and scale are narrower than Brains' EU-GMP footprint.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Owns GW Pharmaceuticals, the pioneer of pharmaceutical-grade cannabinoid drug development (Epidiolex). Most direct comparison point for Brains' strategy of converting naturally-sourced cannabinoids into approved, regulated pharmaceutical products — though Jazz operates further downstream in branded drug commercialization.
Broad incumbents
- Cronos Group: Canadian cannabis operator with pharmaceutical ambitions; Cronos Australia (a Cronos-NewSouthern JV) is an actual Brains Bio distribution partner. Competes with Brains on certain API/finished product lines and is a relevant comparable for global cannabis-pharma strategy.
- Aurora Cannabis: Large Canadian cannabis producer with EU-GMP facilities supplying medical and consumer markets in Europe. Comparable scale of operations and regulatory positioning, though Aurora's product mix is broader and more cultivation-centric than Brains' pure API manufacturer model.
- Canopy Growth Corporation: Major Canadian cannabis operator pursuing pharmaceutical-grade cannabinoid products and global distribution. Broader and more consumer-facing than Brains but overlaps on pharmaceutical-grade CBD positioning and clinical research investments.
- Tilray Brands: Large diversified cannabis operator with pharmaceutical division (Tilray Medical) distributing cannabinoid APIs and finished products globally. Competes with Brains on the nutraceutical/consumer side and overlaps on API supply to pharma, but Tilray's vertically integrated cultivation-and-retail model differs from Brains' pure-play API focus.
Emerging players
- Acreo Health Sciences: EU-based pharmaceutical-grade medical cannabis producer serving wholesalers, pharmacies, and pharma customers across Europe. Comparable in focusing on EU-GMP pharmaceutical-grade supply, though smaller scale than Brains' 12.6-ton annual capacity.
- Botanix Pharmaceuticals: Clinical-stage cannabinoid therapeutics developer focused on dermatology and antimicrobial applications. Similar pharmaceutical-outlook strategy to Brains' pharma division but narrower indication focus and earlier pipeline stage.
- InnoCan Pharma: Israeli-Canadian pharmaceutical company developing cannabinoid-loaded exosome and liposome delivery platforms. Connected to Brains via a Tamar Technologies distribution LOI; comparable in pharmaceutical-grade cannabinoid development though at earlier commercialization stage.
- Cardiol Therapeutics: Clinical-stage pharmaceutical company developing cannabinoid-based therapies for inflammatory heart disease. Comparable in pursuing FDA-style regulated pathways with pharmaceutical-grade CBD formulations, though a single-indication focus rather than platform play.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Brains Bioceutical social profiles
Digital presenceBrains Bioceutical compliance and trust
Trust signalCompliance21 records
Brains Bioceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brains Bioceutical leadership team
Management profileNumber of profiles
Profiles7 records
Brains Bioceutical subsidiaries and ownership
Company hierarchySubsidiaries1 record
Brains Bioceutical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brains Bioceutical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brains Bioceutical
What does Brains Bioceutical do?
Brains Bioceutical is a cannabinoid life sciences company that manufactures EU-GMP certified pharmaceutical-grade active pharmaceutical ingredients (APIs) including CBD, D9-THC, D8-THC, CBN, and CBG at its UK facility. The company leverages these APIs across four pillars: pharmaceutical APIs for drug developers, therapeutic development programs, branded nutraceutical products, and veterinary applications. Revenue is anchored by multi-year B2B supply contracts with pharmaceutical, nutraceutical, and animal health companies globally.
Is Brains Bioceutical a public or private company?
Brains Bioceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Brains Bioceutical founded?
Brains Bioceutical was founded in 2015. It employs 11 to 50 people.
Where is Brains Bioceutical based?
Brains Bioceutical is headquartered in Vancouver, Canada, in the North America region.
How does Brains Bioceutical make money?
Four revenue lines are on record. Pharmaceutical API Supply is the primary driver. The others are nutraceutical Products, pharmaceutical Licensing and contract Manufacturing.
Who are Brains Bioceutical's main competitors?
Direct peers on record are MediPharm Labs and Jazz Pharmaceuticals (GW Pharmaceuticals). Broad incumbents are Cronos Group, Aurora Cannabis, Canopy Growth Corporation and Tilray Brands. Emerging players are Acreo Health Sciences, Botanix Pharmaceuticals, InnoCan Pharma and Cardiol Therapeutics.
Does Brains Bioceutical have an API?
No public API is recorded for Brains Bioceutical.
What industry is Brains Bioceutical in?
Brains Bioceutical's product category is Pharmaceutical Cannabinoid APIs. Its primary akta.pro industry code is HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification), with a secondary code of HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT). Its NAICS code is 325414 and its SIC code is 2836.